Gilead won’t sell MSF its HIV drug. Its shareholders should ask why

Gilead won’t sell MSF its HIV drug. Its shareholders should ask why

Gilead won’t sell MSF its HIV drug. Its shareholders should ask why The company’s refusal to sell lenacapavir to MSF is a failure that will be measured by the number of people who acquire HIV despite possible prevention. Kate Rankin April 30 2026, 7:19am By Melissa Barber, Doctors Without Borders/Médecins Sans Frontières (MSF) USA global health advocacy and policy advisor; Carlota Baptista, MSF HIV/Hepatitis C access advocacy manager; and Mihi…